The estimated Net Worth of Thomas Klein is at least $6.47 Milion dollars as of 18 March 2015. Thomas Klein owns over 80,667 units of XOMA Royalty stock worth over $6,474,005 and over the last 12 years Thomas sold XOMA stock worth over $0.
Thomas has made over 2 trades of the XOMA Royalty stock since 2014, according to the Form 4 filled with the SEC. Most recently Thomas exercised 80,667 units of XOMA stock worth $2,187,689 on 18 March 2015.
The largest trade Thomas's ever made was exercising 80,667 units of XOMA Royalty stock on 18 March 2015 worth over $2,187,689. On average, Thomas trades about 26,889 units every 61 days since 2013. As of 18 March 2015 Thomas still owns at least 238,717 units of XOMA Royalty stock.
You can see the complete history of Thomas Klein stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is C/O XOMA CORPORATION, 2910 SEVENTH STREET, BERKELEY, CA, 94710.
Over the last 22 years, insiders at XOMA Royalty have traded over $74,428,857 worth of XOMA Royalty stock and bought 6,217,869 units worth $44,091,555 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... oraz Bros. Advisors Lp667, L.P.B.... On average, XOMA Royalty executives and independent directors trade stock every 31 days with the average trade being worth of $3,397,377. The most recent stock trade was executed by Owen Hughes on 2 October 2023, trading 1,000 units of XOMA stock currently worth $13,830.
xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.
XOMA Royalty executives and other stock owners filed with the SEC include: